Use of an experimental model to test the efficacy of planned exposure to live porcine reproductive and respiratory syndrome virus

Citation for published version:

Digital Object Identifier (DOI):
10.1128/CVI.00332-07

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Clinical and Vaccine Immunology

Publisher Rights Statement:
Copyright © 2007, American Society for Microbiology

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Use of an Experimental Model To Test the Efficacy of Planned Exposure to Live Porcine Reproductive and Respiratory Syndrome Virus

Tanja Opriessnig,* Rodney B. Baker, and Patrick G. Halbur

Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, Iowa

Received 10 August 2007/Returned for modification 17 September 2007/Accepted 1 October 2007

The objectives of this study were to test the efficacy and safety of planned exposure to porcine reproductive and respiratory syndrome virus (PRRSV) in protecting naïve and previously exposed pigs against PRRSV challenge and to gain information on the dose of PRRSV necessary to induce a protective immune response. Fifty 2-week-old pigs were randomly assigned to one of five groups: a group exposed to a low dose of autogenous PRRSV vaccine (the L-VAC group), a group exposed to a high dose of autogenous vaccine (the H-VAC group), a group exposed to a low dose of a heterologous PRRSV strain (strain SDSU73) prior to planned exposure (the SDSU73-L-VAC group), a group exposed to a high dose of a heterologous PRRSV strain (strain SDSU73) prior to planned exposure (the SDSU73-H-VAC group), and a control group. All groups were challenged with PRRSV VR2385 5 weeks after the planned exposure. Necropsy was done 2 weeks after the PRRSV challenge. The H-VAC, SDSU73-L-VAC, and SDSU73-H-VAC groups had significantly (P < 0.05) less severe clinical disease (sneezing, respiratory scores, and weight gain), significantly (P < 0.05) less severe macroscopic and microscopic lung lesions, and significantly (P < 0.05) lower numbers of PRRSV genomic copy numbers in their sera compared to the results for the control group. Planned exposure to live PRRSV can be used as an inexpensive and effective way to decrease the severity of PRRSV-induced disease following subsequent challenge.

A syndrome known as porcine reproductive and respiratory syndrome (PRRS) emerged simultaneously in Europe and North America at the beginning of the 1990s (1, 22). The “Lelystad virus” was isolated from pigs with PRRS in The Netherlands in 1991 (22). A similar virus was identified in the United States in 1992 (2, 4) and was subsequently found to be closely related to the European isolate, and both viruses were designated porcine reproductive and respiratory syndrome virus (PRRSV). PRRSV is a small, enveloped, positive-sense, single-stranded RNA virus classified in the order Nidovirales, family Arteriviridae, genus Arterivirus (3). PRRSV is associated with reproductive failure in adults and is characterized by mid-to late-term abortions, increased numbers of mummified fetuses, early embryonic death, and infertility (14). In growing pigs, PRRSV infection is associated with respiratory disease and is characterized by labored breathing, sneezing, fever, and increased susceptibility to bacterial diseases, such as those caused by Streptococcus suis (21). PRRSV isolates vary antigenically, genetically, and in their virulence properties (9, 13). North American PRRSV isolates have been found to be more virulent than the Lelystad PRRSV strain when they are compared in the growing pig model (7, 8). It is also clear that North American PRRSV isolates vary in their virulence (9). The degree of immunity generated against heterologous isolates based on genetic or antigenic characteristics is still poorly understood.

PRRSV-induced abortion storms affecting 10 to 25% of the breeding-age females in a herd are not uncommon (6), and the losses due to the postweaning form of the disease can be similarly severe and financially devastating. It has been estimated that the economic impact of PRRSV in the United States is approximately $66.75 million for breeding herds and $493.57 million for growing pigs (16). Strategies that can be used to control PRRSV include the elimination of PRRSV through partial de- and repopulation, herd closure followed by the replacement and introduction of naïve pigs, segregated early weaning, multisite production, and parity segregation strategies. Vaccination approaches with modified live virus products have proved successful in experimental settings; however, failures have been reported in the field (10) and vaccine-like isolates of PRRSV have been recovered from cases of reproductive failure in breeding herds or respiratory disease in growing pigs, suggesting that reversion to virulence may occur under some circumstances (17).

Veterinarians are increasingly relying on natural or planned exposure to the farm-specific strain of PRRSV to induce long-term immunity in the herd. Planned exposure in the past has most commonly been done by putting infected pigs in contact with naïve breeding stock or feeding naïve breeding stock aborted fetuses or tissues from infected pigs. These approaches may be unreliable in getting the targeted population consistently infected in a timely manner. Because of this, some veterinarians have initiated the injection of serum from PRRSV-infected pigs into breeding-age animals to ensure exposure to the resident strain (1, 20). This procedure has not been well described or tested in a controlled setting for safety or efficacy. The main objective of this study was to test the efficacy and safety of a live autogenous PRRSV vaccine to protect naïve or

* Corresponding author. Mailing address: Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011. Phone: (515) 294-1950. Fax: (515) 294-3564. E-mail: tanjaopr@iastate.edu.

Published ahead of print on 10 October 2007.
Table 1. Experimental design used to test the efficacy of planned injection of PRRSV to protect pigs against subsequent exposure to PRRSV

<table>
<thead>
<tr>
<th>Group</th>
<th>Designation</th>
<th>Inoculum at 3 wks of age</th>
<th>Content of serum injected at 8 wks of age*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>L-VAC</td>
<td>None</td>
<td>Low</td>
</tr>
<tr>
<td>2</td>
<td>H-VAC</td>
<td>None</td>
<td>High</td>
</tr>
<tr>
<td>3</td>
<td>SDSU73-L-VAC</td>
<td>SDSU73*</td>
<td>Low</td>
</tr>
<tr>
<td>4</td>
<td>SDSU73-H-VAC</td>
<td>SDSU73*</td>
<td>High</td>
</tr>
<tr>
<td>5</td>
<td>Controls</td>
<td>None</td>
<td>None</td>
</tr>
</tbody>
</table>

*Each group had 10 pigs. The pigs in all groups were inoculated with strain VR2385 at 13 weeks of age.
*PRRSV genomic copy numbers were determined by quantitative PCR. Low, approximately 10^7 PRRSV strain VR2385 genomic copies per 2 ml; high, approximately 10^9 PRRSV strain VR2385 copies per 2 ml.
*Groups 3 and 4 received approximately 10^5 TCID50s of SDSU73 in a 2-ml volume.

Previously exposed pigs against PRRSV challenge. The second objective was to gain more information on the PRRSV dose that is able to induce a protective immune response yet minimal disease.

Materials and Methods

Animals. Fifty-four 2-week-old, segregated, ear weaned, crossbred pigs were purchased from a herd free of PRRSV and Mycoplasma hyopneumoniae, as determined on the basis of regular serological testing. The sows in this herd were routinely vaccinated for swine influenza virus (SIV) and porcine parvovirus (PPV).

Experimental design, housing, and feeding. The experimental design of the study is summarized in Table 1. The pigs were included in one of five groups: a group exposed to a low dose of autogenous PRRSV vaccine (the L-VAC group), a group exposed to a high dose of autogenous homologous vaccine (the H-VAC group), a group exposed to a low dose of a heterologous PRRSV strain (strain SDSU73) prior to planned exposure (the SDSU73-L-VAC group); a group exposed to a high dose of a heterologous PRRSV strain (strain SDSU73) prior to planned exposure (the SDSU73-H-VAC group); and a control group.

On the day of delivery, the pigs were randomly assigned to five groups with 10 pigs and one group with four pigs (serum donor pigs). All groups were housed in separate rooms in pens (2 by 2.5 m) on the floor and equipped with one nipple drinker and one self-feeder. The experimental protocol was approved by the Iowa State University Institutional Animal Care and Use Committee.

PRRSV isolates. PRRSV isolate VR2385 was recovered from a 160-sow herd in southwestern Iowa that had experienced severe respiratory disease in 3- to 16-week-old pigs and high numbers of late-term abortions in 1991 (8). VR2385 has a restriction fragment length polymorphism pattern of 1-3-4. Highly virulent isolate SDSU73 was recovered from a sow herd that experienced a severe epidemic of atypical PRRS in 1996 (14).

The restriction fragment length polymorphism pattern of SDSU73 is 1-4-4. The nucleic acid homology between SDSU73 and the VR2385 is 76%, based on sequencing of open reading frame 5 (ORF5).

Serology. Blood samples were collected on the arrival of the pigs at the research facility (when they were 2 weeks of age) and weekly thereafter through the duration of the study.

PRRSV ELISA. The serum samples taken on the arrival of the pigs at the research facility, on the day of VR2385 virus injection, on the day of VR2385 challenge, and at necropsy were tested for the presence of antibodies to PRRSV by a commercial PRRSV enzyme-linked immunosorbent assay (ELISA; HerdChek PRRS virus antibody test kit 2XR; IDEXX Laboratories, Inc., Westbrook, MA). Samples were considered positive if the sample-to-positive ratio was 0.4 or greater.

PRRSV FFN assay. A fluorescent focus neutralization (FFN) assay for determination of the amount of VR2385-specific neutralizing antibodies was done with sera collected on the day of VR2385-positive serum injection (5 weeks after SDSU73 inoculation) and 5 weeks later, on the day of VR2385 challenge, according to the protocols routinely performed at the Veterinary Diagnostic Laboratory at Iowa State University.

PRRSV quantification. The extraction of RNA from the sera collected on the day of PRRSV inoculation and at 7 and 14 days after PRRSV inoculation was performed by using a QiAamp viral RNA mini kit (Qiagen, Valencia, CA). Primer-probe combinations specific for ORF7 of the North American PRRSV strain (primer PRRSorfF; [TGTCGATTCCGAGGARATAGG TTAC], primer PRRSorfRF7 [ATCAGGCACAGATRTGATG], and probe PRRSorfPR7 [FAM-TGTOGAGTTATGYTGGCC, where FAM is 6-carboxyfluorescein]) and the ORF7 of the European PRRSV strain (primer LELYRTF [GCTGAAAGATGCRTYCGGCA], primer LELYRTR [GCAGYTCCTGGCCTTGAT], and probe LELYRTP [VIC-TGCAATCAGTYGCACAG]) were used (18). The PCR mixture consisted of 5 μl RNA template and 20 μl PCR master mixture. The master mixture contained 0.35 μl of the mixture from the QuantiTect probe reverse transcriptase PCR kit (Qiagen) with the magnesium chloride concentration adjusted to 6 mM; 025 μl (1.25 U) of HotStar Taq (Qiagen); 800, 800, and 275 nM forward primers, reverse primer and probe, respectively. The forward primers, reverse primers, and detection probes for the European PRRSV strain, respectively. Each reaction mixture included five progressive 1:10 dilutions of a known genomic copy number of PRRSV that served to generate a standard curve. Each plate was run in a sequence detection system (GeneAmp 7900; Applied Biosystems, Foster City, CA) under company-specific conditions (30 min at 50°C and 15 min at 95°C, followed by 35 cycles of 15 s at 94°C and 60 s at 60°C).

Serum donor pigs. Four serum donor pigs were inoculated intranasally at 3 weeks of age with 2 ml of VR2385 at 10^5 50% tissue culture infective doses (TCID50s). At 7 days postinoculation, blood was drawn and was confirmed to be positive for PRRSV nucleic acids by reverse transcriptase PCR. The pigs were killed, and blood was collected for serum injection. Within 30 min, the blood was transported to the laboratory on ice, centrifuged, and stored at –20°C until further use.

Inoculation of pigs with a heterologous isolate of PRRSV. At 3 weeks of age, 5 weeks before VR2385-positive serum injection, the pigs in the SDSU73-L-VAC and SDSU73-H-VAC groups were inoculated intranasally with 2 ml of passage 2 of SDSU73 at 10^5 TCID50s (Table 1).

PRRSV-positive serum injection. On the day of planned exposure by serum injection, the donor serum was thawed and the amount of PRRSV genomic copies was determined by quantitative real-time PCR. During the time period preceding the real-time PCR, the sera were stored at +4°C on ice. Serum from one pig that contained approximately 2.18 × 10^9 PRRSV copies per 2 ml and another 30 ml was prepared to contain approximately 10^7 virus particles per 2 ml. The final serum sample for each serum injection was kept on ice for approximately 30 min until the product of the PRRSV vaccine preparations was determined by titration and was found to be 10^17 TCID50s in the high-dose groups and 10^16 TCID50s in the low-dose groups.

Postvaccination PRRSV challenge. Five weeks after the injection with the live autogenous vaccine, all pigs were challenged intranasally with 2 ml PRRSV strain VR2385 at a dose of 10^9 TCID50s. At this time the pigs were 13 weeks old.

Clinical evaluation. The pigs were monitored daily and were scored for the severity of clinical respiratory disease, with the scores ranging from 0 (normal) to 6 (severe dyspnea and abdominal breathing) (8). In addition, the pigs were vaccinated against clinical signs and behavioral changes, including sneezing and lethargy. Rectal temperatures were recorded daily. The pigs were weighed weekly until PRRSV challenge and at necropsy.
RESULTS

PRRSV-specific IgG antibodies. On their arrival at the research facilities, all pigs were negative for PRRSV-specific immunoglobulin G (IgG) antibodies (Fig. 1). At the time of injection with the live autogenous vaccine, all pigs in the SDSL73-L-VAC and SDSL73-H-VAC groups, which had been exposed to SDSL73 5 weeks earlier, had seroconverted to PRRSV, whereas the PRRSV-naive groups (the L-VAC, H-VAC, and control groups) had not. On the day of VR2385 challenge, all groups except the controls had seroconverted to PRRSV. At the termination of the study, all pigs in all groups were positive for PRRSV-specific antibodies, as determined by ELISA (Fig. 1).

Anti-VR2385-specific neutralizing antibodies. On the day of injection with the live autogenous vaccine, the strain SDSL73-treated groups had significantly \((P < 0.003)\) larger amounts of neutralizing antibodies compared to those in all other groups (Fig. 2). On the day of VR2385 challenge, all groups that received an injection with the live autogenous PRRSV vaccine had significantly \((P < 0.001)\) larger amounts of neutralizing antibodies than the controls (Fig. 2).

Additional serology. On their arrival at the research facility, all pigs had some level of passively acquired antibodies to PPV and PCV type 2 (PCV2), the titers of antibodies to both of which decayed over time. None of the control pigs seroconverted to PPV or PCV2 during the course of the experiment. At the termination of the experiment, all pigs were negative for antibodies specific to PPV and PCV2 and for antibodies specific to H3N2 and H1N1 SIV.

Clinical disease. After injection of the pigs with the live autogenous PRRSV vaccine, individual pigs in all groups developed fevers, with their temperatures ranging from 40 to 40.5°C, and had periods of labored breathing. For the 5 weeks postvaccination, there were no significant differences among the groups injected with the live autogenous PRRSV vaccine, as determined by measurement of their respiratory scores and rectal temperatures. However, the nonexposed controls had significantly \((P < 0.0014)\) higher average daily weight gains compared to those for the pigs in all other groups that received the injection of live autogenous PRRSV vaccine. In the period after challenge with VR2385, there were pigs in all groups that experienced increased respiratory scores; however, there were no differences in respiratory scores among the groups. The rectal temperatures were significantly \((P < 0.001)\) higher in the controls, and the controls had significantly \((P < 0.05)\) reduced average weight gains compared to those for pigs in the groups that had previously been inoculated with heterologous isolate SDSL73 and subsequently injected with the live autogenous PRRSV vaccine containing VR2385 (Table 2).

PRRSV genomic copy numbers in sera. The data on the PRRSV genomic copy numbers in sera are summarized in Table 3. There was a significantly \((P < 0.001)\) higher incidence of PCR-positive pigs, and on postinoculation days 7 and 14 the PRRSV genomic copy numbers were significantly \((P < 0.001)\) higher in the controls than in all other groups. Among the controls, 80% of the pigs were positive for...
TABLE 2. Average daily weight gain from the time of PRRSV strain VR2385 challenge to the day of necropsy.

<table>
<thead>
<tr>
<th>Group</th>
<th>Avg daily wt gain (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-VAC</td>
<td>986.4 ± 48.6*</td>
</tr>
<tr>
<td>H-VAC</td>
<td>954.9 ± 71.5**</td>
</tr>
<tr>
<td>SDSU73-L-VAC</td>
<td>1,016.1 ± 107.3*</td>
</tr>
<tr>
<td>SDSU73-H-VAC</td>
<td>711.6 ± 67.6**</td>
</tr>
</tbody>
</table>

*Average daily weight gain from 0 to 14 days after PRRSV strain VR2385 inoculation. Values are means ± SE. Different symbols (* and **) within the column indicate significant (P < 0.05) differences in group mean values. Values with both symbols are not significantly different from the other values.

TABLE 3. Incidence of PRRSV genomic copies in serum on day of PRRSV challenge and days 7 and 14 postinoculation.

<table>
<thead>
<tr>
<th>Group</th>
<th>Incidence (no. of PRRSV-positive pigs/total no. of pigs in group [group mean of log-transformed data ± SE]) on postinoculation day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0/10 (0.0 ± 0.0)</td>
</tr>
<tr>
<td>L-VAC</td>
<td>0/10 (0.0 ± 0.0)</td>
</tr>
<tr>
<td>H-VAC</td>
<td>0/10 (0.0 ± 0.0)</td>
</tr>
<tr>
<td>SDSU73-L-VAC</td>
<td>1/10 (0.2 ± 0.2)</td>
</tr>
<tr>
<td>SDSU73-H-VAC</td>
<td>0/10 (0.0 ± 0.0)</td>
</tr>
<tr>
<td>Control</td>
<td>0/10 (0.0 ± 0.0)</td>
</tr>
</tbody>
</table>

*Different symbols (* and **) within a column indicate significant (P < 0.001) differences in group mean values and incidences.

TABLE 4. Comparison of severities of macroscopic and microscopic lung lesions in PRRSV-infected pigs.

<table>
<thead>
<tr>
<th>Group (no. of pigs)</th>
<th>Macroscopic lung lesion score</th>
<th>Microscopic lung lesion score</th>
</tr>
</thead>
<tbody>
<tr>
<td>L-VAC (10)</td>
<td>20.3 ± 3.1**</td>
<td>1.6 ± 0.3**</td>
</tr>
<tr>
<td>H-VAC (10)</td>
<td>18.2 ± 3.4*</td>
<td>0.7 ± 0.2*</td>
</tr>
<tr>
<td>SDSU73-L-VAC (10)</td>
<td>10.0 ± 3.6*</td>
<td>1.1 ± 0.3*</td>
</tr>
<tr>
<td>SDSU73-H-VAC (10)</td>
<td>11.6 ± 3.1*</td>
<td>1.4 ± 0.2*</td>
</tr>
<tr>
<td>Control (9)</td>
<td>34.9 ± 5.1**</td>
<td>2.7 ± 0.4**</td>
</tr>
</tbody>
</table>

*The range for the macroscopic lung lesion incidence is 0 to 100%; the range for the microscopic lung lesion score is 0 to 6. Different symbols (* and **) within a column indicate significant (P < 0.001) differences in group mean values and incidences. Values with both symbols are not significantly different from the other values.

The main objective of this study was to test the efficacy and safety of the live autogenous PRRSV vaccine for the protection of naïve or previously exposed pigs against homologous PRRSV challenge in a controlled setting. Under the conditions of this study, the live autogenous PRRSV vaccine utilized was effective in partially protecting naïve pigs and pigs previously exposed to a heterologous PRRSV strain against subsequent PRRSV challenge, as measured by the decreased length and levels of viremia and the decreased severity of PRRSV-induced gross and microscopic lesions. This is the first controlled experiment to have further documented the efficacy of a procedure that has been used extensively in the field.

On the basis of the macroscopic lung lesion scores, repeated exposure was more protective than a single exposure. However, the microscopic lung lesion scores neither completely reflected the macroscopic lesion scores nor completely supported cross-protection. The slight discordance of the macroscopic lesion scores and the microscopic lesion scores can be explained by the fact that the macroscopic lesion score accounts for the severity and the extent of lesions, whereas the microscopic lung lesion score accounts for severity only. For example, a lesion might be mild but diffuse. This would result in a low microscopic lesion score but a moderate macroscopic lesion score.

Fano et al. (5) reported a significant (P < 0.05) reduction in the prevalence of PRRSV antibody-positive pigs 1 year after they implemented live autogenous PRRSV vaccination of incoming gilts in a Mexican swine production system. Similarly, Hill et al. (9a) reported a marked improvement of sow herd stability after serum autogenous vaccine interventions, as determined by measurement of the reproductive performance of the breeding herd and the incidence of viremia in weaned pigs in the United States. In contrast to these studies, we tested our protocol under experimental conditions with the growing pig model.

The use of a live autogenous PRRSV vaccine may be justified in herds in which currently available commercial modified live virus PRRSV vaccines have failed. However, those who use planned exposure must understand the risks. Experiences...
from the field document that short-term losses immediately following the use of the live autogenous product in pregnant animals are variable but can be substantial (R. Baker, personal communication). Similarly, there is evidence that under certain conditions, the commercially approved, live attenuated PRRSV vaccines can also revert to virulence (17).

Reports of abortion induction in sows previously exposed to apparently homologous isolates also frequently occur (R. Baker, personal communication). This may be a consequence of determining the degree of homology entirely on the basis of the sequences of ORF5, which may not fully represent antigenic diversity or similarity.

 Killed autogenous vaccines have also been used in breeding herds, particularly to booster immunity from previous natural exposure (M. McCaw, personal communication).

It has been shown that PRRSV-specific antibodies are effective in reducing PRRSV-associated disease, and some level of heterologous protection has been demonstrated; however, the protection appears to be strain specific (12). Osorio et al. (19) found that a cocktail of PRRSV IgG can confer protective immunity against PRRSV-induced reproductive failure in gilts. In contrast, there is also research that supports the idea that small amounts of antibodies accelerate PRRSV binding and entrance into macrophages and, subsequently, increase the incidence of disease (23). Practitioners have expressed concern that the immunity present in breeding-age animals previously exposed to an isolate of PRRSV may interfere with the development of protective immunity against new isolates (anergy) that enter the herd and against isolates that are utilized in updated autogenous live vaccine regimens.

Other risk factors from the use of serum injections for planned exposure to PRRSV must be considered. One issue is the risk of the spread of other known and unknown disease agents which may be present in raw serum. To minimize this risk, practitioners often request PCR for other agents, such as porcine circovirus type 2, in aliquots of the serum that they intend to use and use only those batches in which certain other agents were not found. It should be pointed out that diagnostic laboratories typically look for established economically important agents. Numerous other agents are potentially present in these autogenous serum vaccines. Porcine endogenous retroviruses, lymphotrophic herpesviruses, teschoviruses, pestiviruses, Chlamydia spp., and a host of other likely candidates should be considered potential risks. Although the distribution of these potential pathogens is likely ubiquitous within a herd, the long-term consequences of the synthetic transmission and propagation of these other viruses may largely be underappreciated.

The results of this study indicate that planned exposure to live PRRSV in serum can be used as an inexpensive and effective way to decrease the severity of PRRSV-induced disease following subsequent challenge, regardless of whether the pigs had been previously exposed to a heterologous strain of PRRSV. However, the success of this procedure also likely depends on the scenario for the individual herd. Precautions should be taken to confirm that the serum does not contain unintended viruses, and the use of mass serum injections should be monitored closely.

**ACKNOWLEDGMENTS**

This study was funded by a grant from the Iowa Livestock Health Advisory Council.

PRRSV strain SDSU73 was kindly provided by Boehringer Ingelheim Vetmedica Inc. We thank Shan Yu and Eileen Thacker for providing PRRSV strain VR2385 and Josh Bowden for assistance with the animal work.

**REFERENCES**


